Participated · Series A · Jun 2024

엘에스바이오 develops a fermented bioactive compound called LS-1000 and manufactures dietary supplements using that substance. The company has launched the LS-1000 supplement '디알프리' and a hangover-relief/energy drink '화깨수', which sell online and offline. Its business model reinvests profits from the dietary supplement business into development of natural-product pharmaceuticals. The recent bridge funding will be used to expand the company’s supplement product line and to prepare preclinical studies for drug development. Management says the ultimate goal is to develop a diabetes treatment and a pancreatic-function improvement drug. The company was selected for the government TIPS program and secured two years of R&D funding to support those efforts. CEO Jang Daeyong has stated a plan to validate LS-1000’s anti-diabetic efficacy, complete preclinical work, and enter clinical Phase 1 by 2025.

Participated · Series A · May 2024

넥스트페이먼츠 develops AI-driven smart store solutions that analyze in-store data to improve customer experience and operational efficiency for small merchants. The company offers conversational ordering (AI Order Assistant) and store management tools (AI Store Management Assistant) and has been enhancing a NextAI assistant using OpenAI's API. 넥스트페이먼츠 participates in government smart store technology programs to accelerate SMB digitalization and operates an innovation lab called 엔샵(N#). It has established global partnerships with Samsung, LG, OpenAI, Microsoft, AWS and Otter to support product development and market entry. The company plans to pursue global expansion with a focus on North America and Japan and is running POCs in Canada and the U.S. following its recent Series A financing.